SG11201909783VA - Inhibitors and antagonists of gpr84 for the treatment of endometriosis - Google Patents
Inhibitors and antagonists of gpr84 for the treatment of endometriosisInfo
- Publication number
- SG11201909783VA SG11201909783VA SG11201909783VA SG11201909783VA SG 11201909783V A SG11201909783V A SG 11201909783VA SG 11201909783V A SG11201909783V A SG 11201909783VA SG 11201909783V A SG11201909783V A SG 11201909783VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gpr84
- endometriosis
- pct
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIPO I PCT olimion ono oIIIOHDIDIIl 11°1°111°1111mo Hs (10) International Publication Number WO 2018/210822 Al (51) International Patent Classification: A61K 31/00 (2006.01) A61P 29/00 (2006.01) A61K 31/20 (2006.01) Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (21) International Application Number: (22) International Filing Date: PCT/EP2018/062544 Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 15 May 2018 (15.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17171351.4 16 May 2017 (16.05.2017) EP (71) Applicant: BAYER PHARMA AKTIENGESEL- LSCHAFT [DE/DE]; Miillerstr. 178, 13353 Berlin (DE). (72) Inventors: SACHER, Frank; Erich-Weinert-Str. 134, 10409 Berlin (DE). OBENDORF, Maik; Am Horn 13e, 99425 Weimar (DE). LANGER, Gernot; Mainstr. 32, 14612 Falkensee (DE). MARTINEZ, ESTRADA, Fer- nando; 62 Church Road, GU8 5JD Milford, Godalming (GB). OPPERMANN, Udo; Foxcombe Road, Peggy's Cot- tage, OX1 5DQ, Oxford (GB). SHANG, Catherine; 4/10 Bruce St, Toorak, Melbourne, 3142 (AU). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Mon- heim am Rhein NRW (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). cc O (54) Title: INHIBITORS AND ANTAGONISTS OF GPR84 FOR THE TREATMENT OF ENDOMETRIOSIS 00 (57) : The present invention relates to an antagonist or inhibitor of G protein-coupled receptor 84 (GPR84) for use in the O treatment and/or prevention of a patient suffering from, at risk of developing, and/or being diagnosed for endometriosis, as well as methods of screening for such antagonist or inhibitor as well as methods for diagnosis. O
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17171351.4A EP3403649A1 (en) | 2017-05-16 | 2017-05-16 | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
PCT/EP2018/062544 WO2018210822A1 (en) | 2017-05-16 | 2018-05-15 | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909783VA true SG11201909783VA (en) | 2019-11-28 |
Family
ID=58745052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909783V SG11201909783VA (en) | 2017-05-16 | 2018-05-15 | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210401823A1 (en) |
EP (2) | EP3403649A1 (en) |
JP (1) | JP2020519662A (en) |
KR (1) | KR20200003830A (en) |
CN (1) | CN110573146A (en) |
AR (1) | AR111801A1 (en) |
AU (1) | AU2018269328A1 (en) |
BR (1) | BR112019023999A2 (en) |
CA (1) | CA3063489A1 (en) |
MX (1) | MX2019013734A (en) |
PE (1) | PE20191746A1 (en) |
SG (1) | SG11201909783VA (en) |
TW (1) | TW201900214A (en) |
WO (1) | WO2018210822A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111012782B (en) * | 2019-12-27 | 2023-08-04 | 郑州大学第一附属医院 | GPR84 inhibitor of G protein coupled receptor and application thereof |
WO2021173660A1 (en) * | 2020-02-25 | 2021-09-02 | The Texas A&M University System | Methods for treating endometriosis |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE219517T1 (en) | 1995-08-18 | 2002-07-15 | Morphosys Ag | PROTEIN/(POLY)PEPTIDE LIBRARIES |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
DE60301953T2 (en) | 2002-03-05 | 2006-07-27 | Artemis Pharmaceuticals Gmbh | MICE DERIVED FROM INNOVATION MALE DERIVED FROM EMBRYONIC STEM CELLS |
GB0414798D0 (en) * | 2004-07-01 | 2004-08-04 | Paradigm Therapeutics Ltd | Receptor |
WO2007027661A2 (en) | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
AR056142A1 (en) | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
AR089284A1 (en) * | 2011-12-22 | 2014-08-13 | Galapagos Nv | DIHYDROPIRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
GB201122146D0 (en) | 2011-12-22 | 2012-02-01 | Galapagos Nv | Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions |
US9708312B2 (en) | 2012-12-20 | 2017-07-18 | Galapagos Nv | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) |
GB201411241D0 (en) | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2017
- 2017-05-16 EP EP17171351.4A patent/EP3403649A1/en not_active Withdrawn
-
2018
- 2018-05-15 US US16/614,185 patent/US20210401823A1/en not_active Abandoned
- 2018-05-15 BR BR112019023999-5A patent/BR112019023999A2/en not_active Application Discontinuation
- 2018-05-15 CN CN201880028967.7A patent/CN110573146A/en active Pending
- 2018-05-15 KR KR1020197033271A patent/KR20200003830A/en unknown
- 2018-05-15 MX MX2019013734A patent/MX2019013734A/en unknown
- 2018-05-15 EP EP18728528.3A patent/EP3624781A1/en not_active Withdrawn
- 2018-05-15 AU AU2018269328A patent/AU2018269328A1/en not_active Abandoned
- 2018-05-15 JP JP2019563137A patent/JP2020519662A/en active Pending
- 2018-05-15 WO PCT/EP2018/062544 patent/WO2018210822A1/en unknown
- 2018-05-15 PE PE2019002392A patent/PE20191746A1/en unknown
- 2018-05-15 CA CA3063489A patent/CA3063489A1/en not_active Abandoned
- 2018-05-15 SG SG11201909783V patent/SG11201909783VA/en unknown
- 2018-05-16 AR ARP180101292A patent/AR111801A1/en unknown
- 2018-05-16 TW TW107116520A patent/TW201900214A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3624781A1 (en) | 2020-03-25 |
US20210401823A1 (en) | 2021-12-30 |
TW201900214A (en) | 2019-01-01 |
WO2018210822A1 (en) | 2018-11-22 |
CA3063489A1 (en) | 2018-11-22 |
CN110573146A (en) | 2019-12-13 |
MX2019013734A (en) | 2020-01-15 |
KR20200003830A (en) | 2020-01-10 |
BR112019023999A2 (en) | 2020-06-30 |
AU2018269328A1 (en) | 2019-11-07 |
JP2020519662A (en) | 2020-07-02 |
PE20191746A1 (en) | 2019-12-12 |
AR111801A1 (en) | 2019-08-21 |
EP3403649A1 (en) | 2018-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201809082WA (en) | Nlrp3 modulators | |
SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201408261UA (en) | Syringe | |
SG11201806401YA (en) | G protein-coupled receptor (gpcr) modulation by imipridones | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201408279QA (en) | Social sharing of security information in a group | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
SG11201909003YA (en) | Integrated vascular access device and anchor pad | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201408808WA (en) | Method and system for treatment of biological tissue |